| DC Field | Value | Language |
|---|
| dc.contributor.author | Novikov, V. E. | - |
| dc.contributor.author | Usacheva, N. E. | - |
| dc.contributor.author | Myakisheva, T. V. | - |
| dc.date.accessioned | 2022-05-11T12:16:50Z | - |
| dc.date.available | 2022-05-11T12:16:50Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.citation | Novikov, V.E. Modern approaches to pharmacotherapy of tuberculosis infection in children / V.E. Novikov, N.E. Usacheva, T.V. Myakisheva // Research Results in Pharmacology. - 2021. - Vol.7, №4.-P. 47-53. - Doi: 10.3897/rrpharmacology.7.66627. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46662 | - |
| dc.description.abstract | Anti-tuberculosis drugs (anti-TB drugs) are divided into 3 lines, taking into account drug sensitivity in Mycobacterium tuberculosis (MBT). First-line anti-TB drugs (basic) are used to treat TB caused by drug-susceptible MBT. Second- and third-line (reserve) drugs are recommended for the treatment of MBT-induced multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, respectively | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | drug resistance | ru |
| dc.subject | mycobacterium tuberculosis | ru |
| dc.subject | anti-tuberculosis drugs | ru |
| dc.subject | tuberculosis chemotherapy regimens | ru |
| dc.subject | tuberculosis infection in children | ru |
| dc.title | Modern approaches to pharmacotherapy of tuberculosis infection in children | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 7, № 4
|
